341 results about "Hyperuricemia" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention provides a composition containing dotenorad and a xanthinase inhibitor as well as a preparation method and application of the composition, and belongs to the technical field of pharmacy. The composition provided by the invention comprises dotenorad, a xanthinase inhibitor and at least one pharmaceutically acceptable additive. The composition prepared by the invention has good stability and can be used for clinically treating gout and hyperuricemia.

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention provides lactobacillus fermentum as well as a compound preparation and application thereof, and relates to the technical field of microorganisms. Compared with a strain in the prior art, the lactobacillus fermentum HXJS4-1 disclosed by the invention has a better effect in the aspect of nucleoside degradation and can realize rapid nucleoside degradation. In addition, the compound has a stronger inhibition effect on xanthine oxidase, and the activity of the xanthine oxidase is effectively reduced. In mouse experiments, the strain also has an obvious uric acid reducing effect, also has a certain anti-inflammatory effect, can be used in the prevention and treatment process of hyperuricemia and gout, and provides a new probiotic or drug material for the treatment of hyperuricemia and gout. In addition, eating of the strain has no obvious influence on indexes of a sample body, and it is proved that the strain has the characteristic of high safety and can be widely applied to the fields of medicine and food.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The present invention discloses a humanized human-porcine chimeric uricase chimeric mutant. The amino acid sequence of the mutant is shown in SEQ ID NO. 1. The mutant has excellent uric acid level reduction and high homology with human uricase, providing a new option for drug treatment of hyperuricemia.

Provided herein are methods and compositions and kits related to uricase compositions and / or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.

The invention belongs to the technical field of biological medicine, and relates to application of galangal polysaccharide in preparation of a preparation for improving intestinal flora imbalance. The galangal polysaccharide provided by the invention can effectively improve the alteration of intestinal flora, especially improve the alteration of intestinal flora induced by hyperuricemia, the hyperuricemia can cause intestinal barrier injury, then the intestinal flora is translocated to induce the alteration of the intestinal flora, and the galangal polysaccharide can up-regulate Occludin and ZO-1, repair the intestinal barrier injury and improve the integrity of the intestinal tract; after the action of the galangal polysaccharide, the influence on the intra-group diversity Beta diversity of the flora is large, the flora structure deviation caused by hypeluricemia can be reversed, and the intestinal flora structure deviation can be relieved. The galangal polysaccharide provided by the invention is a potential novel prebiotic, has an excellent effect in improving intestinal flora imbalance, and has a good application prospect.

A lactobacillus composition and the use thereof in hyperuricemia, relating to the field of microorganisms. The composition comprises Lactobacillus gasseri BDUP, Lactobacillus fermentum B1B26 and Lactobacillus agilis B13T4. The lactobacillus composition can significantly inhibit the activity of xanthine oxidase XOD in vitro, and, as proved by in-vivo experiments, said probiotic composition can also reduce the content of uric acid in Danio rerio having high uric acid levels and in hyperuricemia model mice and reduce the level of inflammatory factors in mice with hyperuricemia. In addition, the composition has effects obviously superior to that of a single strain and therefore has good development and utilization prospects for treating or preventing and relieving hyperuricemia.

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.

The invention belongs to the technical field of protein peptide preparation, and particularly relates to mushroom peptide prepared based on Maillard reaction and application of the mushroom peptide to preparation of products with the effects of reducing blood pressure, blood sugar, blood fat and uric acid and antioxidant activity. The mushroom peptide disclosed by the invention has the effects of remarkably reducing blood pressure, blood sugar, blood fat and uric acid and resisting oxidation, and can be used as an auxiliary therapeutic agent or functional food for four high diseases such as hypertension, hyperlipidemia, diabetes mellitus and hyperuricemia and oxidative stress related diseases.

The present invention provides a method for establishing a hyperuricemia prediction model using a machine learning algorithm, which belongs to the field of health assessment technology. The embodiment of the present invention uses a UKBB cohort based on a large population as training, and uses an internal test set and a dataset of healthy physical examinees from Southern Hospital as an external test set to establish and verify a reliable and practical stacked multimodal machine learning model trained based on genetic and clinical data, which is used to timely identify HUA phenotypes and early predict gout and metabolic-related outcome risks. The model has excellent performance, exceeding each single machine learning model, and shows satisfactory efficacy. The ISHUA marker can quantify gout risk and metabolic-related results at an early stage, can provide active guidance for daily health examinations and the management of risk factors, and provide valuable information support for clinicians to appropriately manage HUA risk factors after routine health screening.

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention relates to the technical field of biology, and particularly discloses a strain with a uric acid reducing characteristic and a growth-dependent uric acid characteristic, and the microbial preservation number of the strain is GDMCC No.65914. The uric acid reducing strain is screened from pickles by a transparent ring method, the 16S rRNA gene sequence of the uric acid reducing strain is studied, a resource library of the uric acid reducing strain is expanded, resources are provided for research and development of uric acid reducing drugs in the clinical field, non-target strains are effectively removed through a dual specific screening mechanism of uric acid dependent growth verification and liquid fermentation induced uric acid reduction, and the yield of the uric acid reducing strains is increased. The uric acid reduction and uric acid dependence function stability and metabolic specificity of the screened strain are ensured, the high uric acid reduction strain obtained through screening can be directly used for developing a novel microecological preparation or a uric acid reduction preparation, and compared with traditional chemical drugs, the high uric acid reduction strain has the advantages of being high in safety, good in biocompatibility and small in side effect; high-quality strain resources are provided for biological treatment of hyperuricemia and gout and development of uric acid detection reagents.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

Described herein are crystalline forms of (3, 5-dibromo-4-hydroxyphenyl) (2-(1-hydroxyethyl) benzofuran-3-yl-4, 5, 6, 7-d4) methanone, and solvates thereof.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The invention relates to the field of biological medicine, in particular to application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia related diseases. The invention discovers that quercetagetin has a prevention or improvement effect on hyperuricemia and related diseases for the first time. The result of the specific embodiment of the invention shows that the quercetagetin has a good uric acid reducing effect, obviously reduces the activity of uric acid generation participating enzyme, regulates the expression of uric acid transporter mRNA, improves liver injury and kidney injury caused by hyperuricemia, can prevent or relieve hyperuricemia or hyperuricemia-related diseases, and has a good application prospect. The composition can be used for preparing oral tablets and effervescent tablets.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention discloses a targeted screening method and application of a xanthine oxidase inhibitor in radix puerariae, and belongs to the technical field of medicinal chemistry. A surface chemical exchange method is carried out on xanthine oxidase through a ligand fishing technology, ligands of active groups of xanthine oxidase are modified to the surfaces of magnetic metal nanoparticles, the magnetic metal nanoparticles and a to-be-separated solution are incubated together, and then specific components with the xanthine oxidase inhibiting effect are successfully screened out through a UPLC-Q-TOF-MS / MS technology. The combination of the active component and the XOD active site is verified through molecular docking simulation to confirm that the active component is an effective inhibitor. The invention provides a reliable basis for further clinical research and development of drugs for treating hyperuricemia, and has a wide application prospect.

The invention relates to a preparation method and application of sea cucumber intestine polysaccharide. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The invention relates to the field of lactobacillus paracasei, in particular to a preparation method and application of lactobacillus paracasei for improving hyperuricemia, and the preparation method comprises the following steps: activating a lactobacillus paracasei Jlus66 strain through an MRS liquid culture medium at 36-38 DEG C, then adding the activated Jlus66 strain into the MRS liquid culture medium, and culturing at 36-38 DEG C to obtain the lactobacillus paracasei for improving hyperuricemia. And then centrifuging and abandoning supernate to obtain thalli, and dissolving the thalli with normal saline until the concentration of a bacterial suspension is 1 * 10 < 9 > cfu / ml. The invention provides a method for regulating uric acid metabolism by regulating intestinal flora through the lactobacillus paracasei Jlus66 so as to improve hyperuricemia, side effects can be effectively avoided, and the method is a more natural and safer way.

Described herein are crystalline forms of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-d4)methanone, and solvates thereof.